Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Aims</h3><p>Cyclin-dependent kinase 9 (CDK9) is a member of the CDK subfamily and plays a major role in the regulation of transcriptional elongation. It has attracted widespread attention as a therapeutic target for cancer. Here, we aimed to explore novel CDK 9 inhibitors by using a hybrid virtual screening strategy.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Main methods</h3><p>A hybrid virtual screening strategy was constructed with computer-aided drug design (CADD). First, compounds were filtered in accordance with Lipinski's rule of five and adsorption, distribution, metabolism, excretion, and toxicity (ADMET) properties. Second, a 3D-QSAR pharmacophore model was built and used as a 3D query to screen the obtained hit compounds. Third, the hit compounds were subjected to molecular docking studies. Fourth, molecular dynamics (MD) simulations were performed on CDK9 in complex with the final hits to examine the structural stability. Finally, CDK9 kinase biochemical assay was performed to identify the biological activity of the hit compounds.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Key findings</h3><p>Seven hit compounds were screened out. These hit compounds showed drug-like properties in accordance with Lipinski's rule of five and ADMET. Complexes involving the six hit compounds bound to CDK9 exhibited good structural stability in the MD simulation. Furthermore, these six hit compounds had strong inhibitory activity against CDK9 kinase. In particular, hit <strong>3</strong> showed the most promising activity with the percentage of 71%.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Significance</h3><p>The six hit compounds may be promising novel CDK9 inhibitors, and the hybrid virtual screening strategy designed in this study provides an important reference for the design and synthesis of novel CDK9 inhibitors.</p>

Structure-Based Drug Design, Synthesis and Antitumor Activities of Novel CDK7 Inhibitors

Discovery of a Novel Macrocyclic Noncovalent CDK7 Inhibitor for Cancer Therapy

Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors

A Robust Computational Framework for the Optimization of CDK7 Inhibitors as Promising Cancer Therapy

Synthesis, Biological Evaluation and Molecular Docking Studies of Pyrazole Derivatives Coupling with a Thiourea Moiety As Novel CDKs Inhibitors.

Discovery and optimization of thieno[3,2- d ]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7

Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.

Design, Synthesis and Biological Evaluation of Pteridine-7(8H)-one Derivatives As Potent and Selective CDK4/6 Inhibitors

Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes.

Synthesis and Structure-Activity Relationships of Cyclin-Dependent Kinase 11 Inhibitors Based on a Diaminothiazole Scaffold

Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors

Identification of Potential ATP-competitive Cyclin-Dependent Kinase 1 Inhibitors: De Novo Drug Generation, Molecular Docking, and Molecular Dynamics Simulation.

Discovery of 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine as Novel Cyclin-dependent Kinases 4 and 6 Dual Inhibitors via 3<i>D</i>-QSAR and Molecular Simulation

Design, synthesis, and molecular docking study of 3H-imidazole[4,5-c]pyridine derivatives as CDK2 inhibitors.

Using 3D-QSAR and Molecular Docking Insight into Inhibitors Binding with Complex-Associated Kinases CDK8

Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors

Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation

Synthesis, Biological Evaluation, and Molecular Docking Studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline Derivatives As Novel Anticancer Agents

Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors

Development of in Silico Models for Pyrazoles and Pyrimidine Derivatives As Cyclin-Dependent Kinase 2 Inhibitors

Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening